The extent of effect of ruxolitinib cream on itch in patients with atopic dermatitis is assessed.
Atopic dermatitis (AD) severity and time spent managing symptoms have the strongest associations with self-reported disease burden.
For children younger than 6 years, dupilumab significantly improves signs and symptoms of atopic dermatitis.
The efficacies of systemic treatments with dupilumab, tralokinumab, and Janus kinase inhibitors for moderate to severe atopic dermatitis are compared.
The risk for several major neuropsychiatric disorders in a pediatric population with atopic dermatitis is evaluated.
The efficacy and tolerability of ectoine 1% and hyaluronic acid 0.1% containing (EHA) cream is compared with a vehicle cream in children with mild to moderate atopic dermatitis.
A novel study assesses skin barrier function (pH, TEWL and skin hydration) in healthy participants and patients with atopic dermatitis (peri-lesional and lesional skin).
The efficacy and safety of abrocitinib in patients who received previous dupilumab therapy is assessed.
Theoretical annual costs of OTC moisturizer are compared with costs of atopic dermatitis; Medicaid coverage is also reviewed.
The role of formaldehyde and its releasers in contact allergy and allergic contact dermatitis is reviewed.